ArticleJournal of veterinary internal medicine
The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs.Frontiers in veterinary science · 2026Article
- An Exploratory Study of Cannabidiol as an Adjunctive Treatment for Refractory Epilepsy in Dogs.Animals : an open access journal from MDPI · 2025Article
- Enhancing Cannabidiol Apparent Solubility and Oral Delivery: Self-assembled Nanomicelles of Amphiphilic Block Copolymer with γ-Polyglutamic Acid-grafted Cholesterol.Pharmaceutical research · 2025Article
- Field safety and efficacy study with a cannabidiol/cannabidiol acid-rich hemp paste in cats with osteoarthritic pain.Journal of feline medicine and surgery · 2025Article
- Extended Analysis of Status Epilepticus and Cluster Seizures in Dogs in the Context of Overall Epilepsy Incidence: 254 Cases.Animals : an open access journal from MDPI · 2025Article
- Cumulative Effects of Cannabis Oils on Body Temperature, Electrocardiography, Heart Rate Variability, Blood Pressure, and Respiratory Function in Telemetered Dogs.International journal of veterinary science and medicine · 2025Article
- Demographic features, health status, and behavioral changes associated with cannabidiol use in the Dog Aging Project.Frontiers in veterinary science · 2025Article
- Cytotoxicity and Immunomodulatory Effects of Cannabidiol on Canine PBMCs: A Study in LPS-Stimulated and Epileptic Dogs.Animals : an open access journal from MDPI · 2024Article
- Endocannabinoid system and phytocannabinoids in the main species of veterinary interest: a comparative review.Veterinary research communications · 2024Review
- Subthreshold Cannabidiol Potentiates Levetiracetam in the Kainic Acid Model of Temporal Lobe Epilepsy: A Pilot Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Tolerability of 2 and 4 mg/kg Dosing Every 12 Hour of a Cannabidiol- and Cannabidiolic Acid-Rich Hemp Extract on Mixed-Breed Dogs Utilized for Teaching in a Closed Colony.Animals : an open access journal from MDPI · 2024Article
- Evaluation of the effect of cannabidiol administration with and without nonsteroidal anti-inflammatory drugs in dogs with mobility disorders: a prospective, double-blind, crossover, placebo-controlled study.Frontiers in veterinary science · 2024Article
- Pharmacokinetic of two oral doses of a 1:20 THC:CBDFrontiers in veterinary science · 2024Article
- Cannabidiol plasma determination and pharmacokinetics conducted at beginning, middle and end of long-term supplementation of a broad-spectrum hemp oil to healthy adult dogs.Frontiers in veterinary science · 2023Article
- Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy.Journal of veterinary internal medicineArticle
- The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundApproximately 30% of dogs with idiopathic epilepsy (IE) are drug-resistant. Recent studies have suggested cannabidiol (CBD) may be an effective anticonvulsant in dogs with IE.
objectiveTo evaluate the addition of CBD to antiseizure drugs (ASDs) on seizure frequency and to report adverse events in dogs with drug-resistant IE. ANIMALS: Fifty-one dogs. Dogs having at least 2 seizures per month while receiving at least 1 ASD were included in the trial.
methodsDouble-blinded placebo-controlled crossover study. The 5 mg/kg/day dosage met futility requirements after 12 dogs, and a dosage of 9 mg/kg/day was used in the next 39 dogs. Dogs were randomly assigned to receive CBD or placebo for 3 months, with a 1-month washout period between oils. Total numbers of seizures and seizure days were recorded. Diagnostic testing was performed periodically throughout the trial.
resultsAt the 9 mg/kg/day dose, the decrease in total seizure frequency was significant compared with placebo. A 24.1% decrease in seizure days occurred in dogs receiving CBD and a 5.8% increase occurred in dogs receiving placebo (P ≤ .05). No significant difference was found in the number of responders (≥50% decrease in total seizures or seizure days). Liver enzyme activities increased at both dosages. Decreased appetite and vomiting were more common in the CBD phase (P ≤ .05). CONCLUSIONS AND CLINICAL IMPORTANCE: Cannabidiol decreased total seizures and seizure days compared to placebo when administered to dogs PO at 9 mg/kg/day. Liver enzymes should be monitored with administration of CBD in dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.